ZYUS Life Sciences Corporation is a Canada-based life sciences company. It develops and commercializes novel cannabinoid-based pharmaceutical drug candidates for pain management. Its lead research program is focused on developing a highly purified cannabinoid formulation to treat chronic pain due to cancer, musculoskeletal injuries and arthritis. Its pre-and non-clinical studies provide the foundation for clinical investigations of its drug candidates in humans. Its lead/first drug product candidate in this program, Trichomylin softgel capsules, is a fixed dose combination of cannabinoids formulated for treatment of chronic pain in adults. This formulation offers oral administration of highly purified cannabinoids in a controlled dosage. In parallel with the research conducted respecting Trichomylin softgel capsules, it has also identified and commenced research on a second drug candidate. This drug candidate is a cannabinoid-based therapeutic composition for pain management.